Replies to post #1981 on BioPharmX Corp fka BPMX

[Wantcash]

If you read the bold type, he was granted the option to purchase shares at.22. It says purchased, so I'm thinking he paid for them, but he has to be vested before he can cash the in. He only gets to cash in 25% in one year. I just wanted to know if it was purchased by him or company. If it's his money, that's a good sign,imo, that he believes the price is going up. He has "skin in the game".

[Whos_Who]

Also to add to your post,

"shareholders with as little as 5-10 percent ownership can push for their own seats on the board or enact changes at shareholder meetings"

Benefits of Controlling Interest
The upside of holding a controlling interest in a company can come in many forms. First, whether the company is public or private, controlling interest gives a person or group of people massive influence. Since, by definition, the party with controlling interest automatically has the majority vote, controlling interest then allows an individual to veto or overturn decisions made by existing board members. This gives people who have controlling interest in a company the ability to take ownership over the operational and strategic decision-making processes.

Further, in some companies, if an individual has the controlling interest of the company, the company will automatically make that person the chairman of a company's board of directors. This gives the individual with controlling interest even more power than the majority vote. In addition to retaining veto power over a board vote, the individual can effectively make board decisions on their own, including hiring C-level executives.

Finally, controlling interest grants an investor leverage to increase their shareholding stake in a company in the event of a merger or acquisition. For example, in the case of a strategic merger that involves a share swap, the investor holding a controlling interest structures the deal in such a way that they continue to have majority voting power over the new entity.

[Timing101]

Noted and agreed
--
just appointed Sept 12, 2018
---
The 7.4 million , was part of his package , in options.
Normal practice
--
Read his Bio , fully qualified to take this company as he has
done in the past . ENDO... major player below
==========================
BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer
Sep 12, 2018

MENLO PARK, Calif., Sept. 12, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the appointment of David S. Tierney, M.D., as its chief executive officer. Anja Krammer continues to serve in her roles as president and corporate secretary for BioPharmX. Dr. Tierney was also appointed as a director to the board of directors of BioPharmX. BioPharmX Corporation noted that Dr. Tierney is an accomplished healthcare executive with a proven record of achievements leading the growth of both pharmaceutical and medical device companies. Additionally, Dr. Tierney possesses significant experience in successfully developing and commercializing drug delivery platforms, which will be a particularly valuable asset for BioPharmX as it commercializes its own topical dermatology technology.

(PRNewsfoto/BioPharmX Corporation)
---

"We look forward to having a seasoned industry veteran such as David join our team as we advance our topical dermatology clinical programs and commercialization strategies," said Michael L. Hubbard, chairman of the board of directors of BioPharmX Corporation. "David brings a wealth of expertise in medical science, clinical, and regulatory affairs, and in overseeing the advancement of healthcare companies from the product development phase to commercial operations."
---

David Tierney commented, "BioPharmX is on the threshold of an important and exciting growth phase as is evident from the company's robust product pipeline and its lead product candidate being phase 3-ready for acne." He further noted, "I expect advancements in BioPharmX product development to drive increased corporate visibility and transformational changes in dermatologic pharmaceuticals. I am thrilled to have the opportunity to participate and contribute to BioPharmX's growth prospects."
---
About David S. Tierney, M.D.
Prior to his appointment as CEO at BioPharmX, he was president and CEO of Icon Bioscience where he led a team that in 2018 received U.S. FDA approval of its New Drug Application (NDA) for DEXYCU™ (dexamethasone intraocular suspension), a dropless, long-acting therapeutic for treating inflammation associated with cataract surgery. Icon was merged with EyePoint Pharmaceutical in March 2018.
---
Dr. Tierney served as president and chief operating officer of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in 2008. Oceana quickly established a global commercial network and by 2011 was acquired by Salix Pharmaceuticals. In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals. Prior to Valera, Dr. Tierney was president of Biovail Technologies, a drug delivery division of Biovail Corporation - a predecessor to Valeant Pharmaceuticals International. Earlier in his career, he served as senior vice president of drug development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation. Dr. Tierney received his medical degree from Royal College of Surgeons in Ireland.
---
David Tierney is the recipient of two Ernst & Young Entrepreneur of the Year® awards, first in 2005 and again in 2011, respectively, reflecting his accomplishments at Valera and Oceana. He was also featured in the inaugural 2010 Irish Life Science 50, an honor presented by the president of Ireland in conjunction the Irish Voice and Irish America Magazine. Additionally, in 2005, 2006, and 2011, PharmaVOICE 100 named David one of the most inspiring people in health sciences.